One-page resource on non-surgical device evaluation in Africa as of late 2013.
Voluntary Medical Male Circumcision (VMMC) Device Evaluations Map and Table
An Action Agenda to End AIDS: Where are we in realizing the promise of beginning to end AIDS?
Issued in 2013, a year after An Action Agenda to End AIDS was first published, this document gives a status report on key actions and provides priority recommendations.
A Cascade of Hope and Questions: Anticipating results of ARV-based HIV prevention trials
A report designed to help advocates understand results of the 2010 CAPRISA 004 trial and how they related to the research agenda for ARV-based prevention strategies.
A Call to Action on Voluntary Medical Male Circumcision: Implementing a key component of combination HIV prevention
A comprehensive 2012 report from civil society about the state of voluntary medical male circumcision in Africa. Includes priority recommendations and in-depth discussion of factors influencing national scale-up efforts.
A Call to Action on Voluntary Medical Male Circumcision: Executive Summary
This is the executive summary of a 2012 joint civil society report on voluntary medical male circumcision. The document focuses on priority recommendations for action.
From Research to Reality: Investing in HIV prevention research in a challenging landscape
Summary of findings from report on 2012 investment and funding trends in HIV prevention research and development (R&D).
Intermittent PrEP (iPrEP) Research Agenda: Summary of an amfAR/AVAC think tank
A six-page summary of a meeting convened by amfAR and AVAC involving leaders from research and research sponsor agencies. The meeting reviewed the status of biomedical, behavioral and animal research relevant to intermittent PrEP, identifed gaps and priorities for moving forward.
2013 AVAC Report: Research and Reality [Executive Summary]
This year’s AVAC Report is about the new realities of biomedical HIV prevention research. In the last few years we’ve seen major advances, but also have had sobering realizations about the difficulties of developing new HIV prevention options that can succeed both in trials and programs in the real world. Landmark vaccine, microbicide and PrEP trial results energized the biomedical HIV prevention field. Yet, follow-up work from all these trials has been slower than necessary. In the search for new prevention tools for women two recent trials have found very low rates of adherence. These trials have given rise to important questions, not only about women’s willingness to use the test product, but about the research process itself.
We argue that the field needs to take a fast, focused look at fundamental assumptions and missed opportunities across the HIV prevention research field—and retool its approaches so that the next generation of research delivers advances that women and men want and will use.
Px Wire July-September 2011, Vol. 4, No. 3
PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This edition of PxWire includes a feature on the new momentum to end the AIDS epidemic in light of the recent HPTN 052 results; an exploration of the progress in AIDS vaccine research and the need for evolving trial designs to accommodate new trial results such as those from HPTN 052 and iPrEx; and, as always, a centerspread with an updated timeline of biomedical HIV prevention efficacy trials and a world map showing where various strategies are being tested.
PxWire January-March 2011, Vol. 4, No. 1
PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue of PxWire takes inventory of the regulatory, trial-planning and scientific agenda-setting steps that are being taken with respect to recent positive trial results. It reviews ongoing and proposed next steps that have been triggered by the Thai prime-boost AIDS vaccine trial, the CAPRISA 004 microbicide trial and the iPrEx trial of once-daily TDF/FTC for pre-exposure prophylaxis.